Brind.

Brokerage Analysis Highlights Diversification in Indian Pharma Supply Chains

Steady: 0 in the last 7 days Updated oct 16

The latest in this situation

  1. Laurus Labs is shifting focus from building to filling capacity and may participate in Amgen's supply chain.
  2. Brokerage firms provided ratings and analyzed the diversification trends within Indian pharmaceutical supply chains.

How it started

1 report, 1 independent, last reported Oct 13. The briefing below covers this first event.

AI-generated briefing. Brind wrote this from the reports listed below and has updated it as the story developed. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Jefferies equity analysts provided ratings and growth projections for several Indian pharmaceutical companies, including Divi’s Laboratories, Sai Life Sciences, Anthem Biosciences, and Laurus Labs. The analysis noted that the geographical diversification of pharmaceutical supply chains is largely being driven by companies in the US and Europe.

From indiatimes.com

Why it matters

Some supportBrind's analysis of the reports

The brokerage believes that Indian Contract Research and Development Manufacturing Organizations (CRDMOs) that maintain strong relationships with US and European pharmaceutical companies are better positioned to achieve superior long-term financial returns. This trend is driving growth in the sector.

From indiatimes.com

Who's involved

  • Laurus LabsIndian pharmaceutical company that received a Hold rating and target price
  • Torrent PharmaceuticalsIndian multinational pharmaceutical company operating within the sector
  • MSCIAmerican financial service provider that formally included Laurus Labs in its indices
  • founderPerson who holds a leadership role within Laurus Labs
  • Vinod NairResearcher discussed in relation to Laurus Labs' valuation pattern

Who could feel it

Possible knock-on effects

These are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.

  • Torrent PharmaceuticalsSpeculative

    Torrent Pharmaceuticals might experience changes in demand or investment based on the CRDMO diversification trend.

How it developed

Newest first. Tap a step to see who reported it.
  1. Laurus Labs is shifting focus from building to filling capacity and may participate in Amgen's supply chain.Sub-event
  2. Indian CRDMOs are better positioned for diversification, driving supply chain growth.1 source

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped